Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

Response to SARS-CoV-2-vaccines in kidney-transplant recipients (KTR) is severely reduced. Heterologous3rd vaccination combining mRNA and vector vaccines did not increase seroconversion at 4 weeks after vaccination, but evolution of antibody levels beyond the first month remains unknown. We have rec...

Full description

Bibliographic Details
Main Authors: Andreas Heinzel, Eva Schrezenmeier, Florina Regele, Karin Hu, Lukas Raab, Michael Eder, Christof Aigner, Rhea Jabbour, Constantin Aschauer, Ana-Luisa Stefanski, Thomas Dörner, Klemens Budde, Roman Reindl-Schwaighofer, Rainer Oberbauer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Medicine
Subjects:
COVID-19
kidney transplantation
COVID-19 vaccination
heterologous vaccination
third vaccination
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.936126/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.936126/full

Similar Items